RxDoctor Payments Data

Atif Sohail

Interventional Cardiology · Arlington, TXNPI 1265431787

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 28 payments — averaging $46.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$488
  • Medtronic$370
  • Boehringer Ingelheim$80
  • AstraZeneca$65
  • Abbott$63
  • Melinta Therapeutics, LLC$44
  • plus $194 from 8 others

What the payments were for

  • Travel & lodging$79361%
  • Food & beverage$51139%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303 in reported general payments places this provider in the 5th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$191,690
Medicare patients
276
Services billed
1,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin226$284,149
EliquisApixaban51$59,649
EntrestoSacubitril/Valsartan20$29,067
XareltoRivaroxaban19$23,170
OzempicSemaglutide13$21,179
FarxigaDapagliflozin Propanediol21$14,505
Ranolazine ErRanolazine59$5,532
Nitroglycerin PatchNitroglycerin78$3,362
Metoprolol Succinate206$2,653
Midodrine Hcl24$2,351
ClopidogrelClopidogrel Bisulfate115$1,063
Spironolactone132$872
Enalapril Maleate47$773
Carvedilol89$677
SotalolSotalol Hcl24$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$80$284,149226 claims
PfizerEliquis$37$59,64951 claims
Johnson & JohnsonXarelto$33$23,17019 claims
Novo NordiskOzempic$37$21,17913 claims
AstraZenecaFarxiga$65$14,50521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →